Resumen

MAINET GONZALEZ, Damián. Bioethical aspects of pharmacogenomics in the clinical phase of drug development. Rev Cubana Invest Bioméd [online]. 2016, vol.35, n.1, pp. 0-0. ISSN 1561-3011.

The clinical phase in the development of drugs for the treatment of multifactorial diseases is both lengthy and costly. Pharmacogenomics aids this process by providing a better design of clinical trials as well as a selection of patients with a greater probability to effectively respond and fewer adverse reactions to therapeutic candidates. The present bibliographic review is intended to reveal the advantages of pharmacogenomic tests in clinical trials for drug development, explain the ethical, legal and psychosocial consequences of their application, and propose some measures to counteract psychosocial risks. Pharmacogenomic tests were evaluated in a simple, multiple and combined manner, and fulfilled several objectives and functions at the various phases of clinical trials of drugs. Informed consent from the subjects participating in the clinical trials and their evaluation by the Ethical Review Board, actions taken by national regulatory authorities, compliance with public health ministerial regulations, application of international bioethical principles, and analysis of each ethical dilemma according to its specific characteristics, are all measures aimed at enhancing respect for dignity, autonomy and privacy of research subjects and facilitating the application of pharmacogenomics to clinical trials of drugs.

Palabras clave : Bioethics; Pharmacogenomics; Clinical trials; Drug development.

        · resumen en Español     · texto en Español     · Español ( pdf )